WO2005100998A3 - Membrane markers for use in cancer diagnosis and therapy - Google Patents

Membrane markers for use in cancer diagnosis and therapy Download PDF

Info

Publication number
WO2005100998A3
WO2005100998A3 PCT/EP2005/004153 EP2005004153W WO2005100998A3 WO 2005100998 A3 WO2005100998 A3 WO 2005100998A3 EP 2005004153 W EP2005004153 W EP 2005004153W WO 2005100998 A3 WO2005100998 A3 WO 2005100998A3
Authority
WO
WIPO (PCT)
Prior art keywords
proteins
diagnosis
agents
relates
membrane proteins
Prior art date
Application number
PCT/EP2005/004153
Other languages
German (de)
French (fr)
Other versions
WO2005100998A2 (en
Inventor
Silvia Tortola-Perez
Stephanie Lamer
Steffen Heim
Miriam Fuchs
Thomas Buschmann
Volker Seibert
Nikoleta-Kyriaki Fotiadis
Katrin Stedronsky
Joern Meuer
Kirsten Rothmann-Cosic
Tatiana Ilynia
Lueder Fels
Original Assignee
Europroteome Ag
Silvia Tortola-Perez
Stephanie Lamer
Steffen Heim
Miriam Fuchs
Thomas Buschmann
Volker Seibert
Nikoleta-Kyriaki Fotiadis
Katrin Stedronsky
Joern Meuer
Kirsten Rothmann-Cosic
Tatiana Ilynia
Lueder Fels
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Europroteome Ag, Silvia Tortola-Perez, Stephanie Lamer, Steffen Heim, Miriam Fuchs, Thomas Buschmann, Volker Seibert, Nikoleta-Kyriaki Fotiadis, Katrin Stedronsky, Joern Meuer, Kirsten Rothmann-Cosic, Tatiana Ilynia, Lueder Fels filed Critical Europroteome Ag
Publication of WO2005100998A2 publication Critical patent/WO2005100998A2/en
Publication of WO2005100998A3 publication Critical patent/WO2005100998A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention relates to agents and methods for the diagnosis, prognosis and treatment of non-steroid dependent cancer. Specifically, the invention relates to the use of nucleic and amino acid sequences encoding plasma membrane proteins of the invention that are differentially expressed in tumour tissues for the diagnosis of both early and late stage non-steroid specific cancers, cancer prognosis, as well as screening for therapeutic agents that regulate the gene expression and/or biological activity of such proteins. This invention further relates to the biological technologies designed to inhibit the gene expression and/or biological activity of the proteins plasma membrane proteins of the invention, including using agents identified in screening assays described herein, as well as molecules that are complementary to polynucleotide sequences encoding plasmas membrane proteins of the invention and antibody targeting of said proteins. In specific embodiments, the proteins are of human origin.
PCT/EP2005/004153 2004-04-16 2005-04-15 Membrane markers for use in cancer diagnosis and therapy WO2005100998A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04090152.2 2004-04-16
EP04090152 2004-04-16

Publications (2)

Publication Number Publication Date
WO2005100998A2 WO2005100998A2 (en) 2005-10-27
WO2005100998A3 true WO2005100998A3 (en) 2008-06-12

Family

ID=34982085

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/004153 WO2005100998A2 (en) 2004-04-16 2005-04-15 Membrane markers for use in cancer diagnosis and therapy

Country Status (1)

Country Link
WO (1) WO2005100998A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8669380B2 (en) 2009-11-02 2014-03-11 Pfizer Inc. Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2904004B1 (en) * 2006-07-19 2008-09-05 Galderma Res & Dev S N C Snc MODULATORS OF SCARB-1 IN THE TREATMENT OF ACNE OR HYPERSEBORRHEA
GB2442059A (en) * 2006-09-19 2008-03-26 Ist Superiore Sanita Test for cancer of the gastrointestinal tract
MX341883B (en) * 2008-08-05 2016-09-07 Toray Industries Pharmaceutical composition for treatment and prevention of cancer.
DK2733492T3 (en) * 2008-08-05 2016-04-25 Toray Industries Method for detection of cancer
CN103751771B (en) 2008-08-05 2017-09-08 东丽株式会社 Immune inducing agent
AU2011211700B2 (en) * 2010-02-04 2015-06-11 Toray Industries, Inc. Medicament for treating and/or preventing cancer
DK2532366T3 (en) 2010-02-04 2017-01-02 Toray Industries PHARMACEUTICAL COMPOSITION FOR TREATMENT AND / OR CANCER PREVENTION
RU2567657C2 (en) 2010-02-04 2015-11-10 Торэй Индастриз, Инк. Pharmaceutical composition for treating and/or preventing cancer
EP2532365B1 (en) 2010-02-04 2016-05-04 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
KR101805520B1 (en) 2010-02-04 2017-12-07 도레이 카부시키가이샤 Pharmaceutical composition for treatment and/or prevention of cancer
PT2532364T (en) 2010-02-04 2016-07-28 Toray Industries Pharmaceutical composition comprising anti caprin-1 antibodies for treating and/or preventing cancer
KR101968498B1 (en) 2011-08-04 2019-04-12 도레이 카부시키가이샤 Drug composition for cancer treatment and/or prevention
PT2741085T (en) 2011-08-04 2017-06-30 Toray Industries Method for detecting pancreatic cancer
PL2740798T3 (en) 2011-08-04 2017-07-31 Toray Industries, Inc. Cancer treatment and/or prevention drug composition
HUE039219T2 (en) 2011-08-04 2018-12-28 Toray Industries Pharmaceutical composition for treatment and/or prophylaxis of cancer
JP6070191B2 (en) 2011-08-04 2017-02-01 東レ株式会社 Pharmaceutical composition for treatment and / or prevention of cancer
AU2012290949B2 (en) 2011-08-04 2017-03-02 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
PT2740795T (en) 2011-08-04 2017-01-09 Toray Industries Cancer treatment and/or prevention drug composition
IN2014KN01716A (en) 2012-02-21 2015-10-23 Toray Industries
MX360208B (en) 2012-02-21 2018-10-24 Toray Industries Pharmaceutical composition for treatment and/or prevention of cancer.
CA2864869C (en) 2012-02-21 2021-10-19 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
PL2818481T3 (en) 2012-02-21 2020-02-28 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
PT2832365T (en) 2012-03-30 2018-01-24 Toray Industries Pharmaceutical composition for treatment and/or prevention of liver cancer
MX357965B (en) 2012-03-30 2018-08-01 Toray Industries Pharmaceutical composition for treatment and/or prevention of gall bladder cancer.
KR101416147B1 (en) 2012-07-18 2014-07-09 국립암센터 Use of ADCY3 for the Diagnosis and Treatment of Gastric Cancer
ES2718348T3 (en) 2012-07-19 2019-07-01 Toray Industries Method to detect cancer
JP6244912B2 (en) 2012-07-19 2017-12-13 東レ株式会社 Cancer detection method
WO2014179751A1 (en) * 2013-05-02 2014-11-06 The Children's Hospital Of Philadelphia Compositions and methods for the treatment of human immunodeficiency virus infection
WO2014186862A1 (en) * 2013-05-20 2014-11-27 Dlvr Therapeutics Inc. Diagnostic method and assay for sr-b1 expressing cancers
BR112016001753B1 (en) 2013-08-09 2023-10-03 Toray Industries, Inc ANTIBODY, ANTIBODY COMPOSITION, PHARMACEUTICAL COMPOSITION, DNA AND USE OF AN ANTIBODY
CN105301260A (en) * 2015-11-13 2016-02-03 温州医科大学 Breast cancer marker and treatment target protein zero related (PZR) and use thereof
EP4143229A1 (en) 2020-05-01 2023-03-08 NGM Biopharmaceuticals, Inc. Ilt-binding agents and methods of use thereof
CN114540504B (en) * 2022-04-27 2022-07-08 广州万德基因医学科技有限公司 Marker group and system for predicting immune curative effect of lung squamous carcinoma patient

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1033404A1 (en) * 1999-01-29 2000-09-06 F. Hoffmann-La Roche Ag New gene with down-regulated expression in metastatic human melanoma cells
WO2002014500A2 (en) * 2000-08-16 2002-02-21 Chiron Corporation Human genes and gene expression products
US20020160382A1 (en) * 2000-10-11 2002-10-31 Lasek Amy W. Genes expressed in colon cancer
US20030108926A1 (en) * 2000-03-15 2003-06-12 Eos Biotechnology, Inc. Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
WO2004005483A2 (en) * 2002-07-10 2004-01-15 Exelixis, Inc. ADCY3S AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
WO2004015071A2 (en) * 2002-08-07 2004-02-19 Exelixis, Inc. CSNK1GS AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
EP1394182A1 (en) * 2002-07-08 2004-03-03 Europroteome AG Agents and methods for diagnosis and therapy of cancer and cancer risk assessment

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1033404A1 (en) * 1999-01-29 2000-09-06 F. Hoffmann-La Roche Ag New gene with down-regulated expression in metastatic human melanoma cells
US20030108926A1 (en) * 2000-03-15 2003-06-12 Eos Biotechnology, Inc. Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
WO2002014500A2 (en) * 2000-08-16 2002-02-21 Chiron Corporation Human genes and gene expression products
US20020160382A1 (en) * 2000-10-11 2002-10-31 Lasek Amy W. Genes expressed in colon cancer
EP1394182A1 (en) * 2002-07-08 2004-03-03 Europroteome AG Agents and methods for diagnosis and therapy of cancer and cancer risk assessment
WO2004005483A2 (en) * 2002-07-10 2004-01-15 Exelixis, Inc. ADCY3S AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
WO2004015071A2 (en) * 2002-08-07 2004-02-19 Exelixis, Inc. CSNK1GS AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8669380B2 (en) 2009-11-02 2014-03-11 Pfizer Inc. Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives

Also Published As

Publication number Publication date
WO2005100998A2 (en) 2005-10-27

Similar Documents

Publication Publication Date Title
WO2005100998A3 (en) Membrane markers for use in cancer diagnosis and therapy
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
WO2004066941A3 (en) Expression profiles for colon cancer and methods of use
WO2004092405A3 (en) Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof
TNSN05300A1 (en) Treatment with anti-vegf antibodies
WO2003004989A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2006028655A3 (en) Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
MX2010005651A (en) Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof.
WO2005059108A3 (en) Gene expression profiles and methods of use
TW200635946A (en) Binding proteins specific for human matriptase
WO2006027693A3 (en) Tumor specific genes and variant RNAS and uses thereof as targets for cancer therapy and diagnosis
WO2005032495A3 (en) Gene expression profiles and methods of use
WO2005034732A3 (en) Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
WO2007058968A3 (en) Gene expression profiles and methods of use
WO2004098377A3 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
WO2004078035A3 (en) Expression profiles for breast cancer and methods of use
GB0418388D0 (en) Cell therapy
MXPA05006034A (en) Replication protein.
WO2003083102A3 (en) Cancer associated protein phosphatases and their uses
TW200724679A (en) Treatment of disease using an improved regulated expression system
WO2003076610A3 (en) Variants of human kallikrein-2 and kallikrein-3 and uses thereof
IL207012A0 (en) Diagnosis and therapy of cancer using sgp28-related molecules
WO2010036031A3 (en) Pauf-specific human monoclonal antibody, pharmaceutical composition for treating cancer comprising the same and method for detecting cancer using the same
WO2004085614A3 (en) Nucleic acid molecules that are differentially regulated in a bipolar disorder and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC FORM 1205A OF 23-02-2007

122 Ep: pct application non-entry in european phase